SLC5A2 and cancer: Additionally, in another study that assessed the anticancer activity of SGLT-2 inhibitors, it was shown that in concentrations of 5–30 μM canagliflozin, but not dapagliflozin, inhibits the proliferation and clonogenic survival of prostate (PC3, 22RV-1), lung (A549, H1299), liver (HepG2) and breast (MCF7) cancer cells [7].